Biosimilars for Retinal Diseases
SIG Chair: Ashish Sharma, MD
- To strengthen International Retinal Biosimilar Study (Inter- BIOS) Group by involving ranibizumab biosimilar users and thought leaders across the globe
- To publish real world data of ranibizumab biosimilars across the globe under one platform of Inter-BIOS Group
International Retinal Biosimilar Study (Inter- BIOS) Group was formed in 2022 and conducted the first study as an awareness survey entitled “Biosimilars for Retinal Diseases – United States-Europe Awareness Survey (Bio-USER –Survey).” Results of the survey were presented at Euretina 2022 and AAO 2022.